32021R0056
PDA TR 56
Technical Report No. 56 Revised 2016 (TR 56) Application of Phase-Appropriate Quality System and cGMP to the Development of Therapeutic Protein Drug Substance (API or Biological Active Substance)
32016R0056
32014L0056
32014R0056
32009R0056
32012D0056
32011L0056
32008L0056
32002L0056
31998L0056
32000L0056
31990D0056
\u041f\u041d\u0421\u0422 56-2015
Fireproof safes. Requirements and test methods for fire resistance
\u0423\u043a\u0430\u0437 \u041f\u0440\u0435\u0437\u0438\u0434\u0435\u043d\u0442\u0430 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438 \u043e\u0442 30.01.2021 \u2116 56
\u0423\u043a\u0430\u0437 \u041f\u0440\u0435\u0437\u0438\u0434\u0435\u043d\u0442\u0430 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438 \u043e\u0442 07.02.2018 \u2116 56
31984D0056
\u0423\u043a\u0430\u0437 \u041f\u0440\u0435\u0437\u0438\u0434\u0435\u043d\u0442\u0430 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438 \u043e\u0442 12.02.2016 \u2116 56
\u0423\u043a\u0430\u0437 \u041f\u0440\u0435\u0437\u0438\u0434\u0435\u043d\u0442\u0430 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438 \u043e\u0442 05.02.2015 \u2116 56
\u0423\u043a\u0430\u0437 \u041f\u0440\u0435\u0437\u0438\u0434\u0435\u043d\u0442\u0430 \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0439 \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u0438 \u043e\u0442 05.02.2014 \u2116 56